Thursday, July 21, 2022 6:38:52 AM
Opened a position in ADIL.
- Heavy drinkers are the biggest group and in practice are those that get help and treatment more than the very heavy drinkers. Very heavy drinkers have a stronger physiologic addiction and are more in denial.
- Stat. Sig. in heavy drinkers (0.003) is super for a near 90% response. Splitting groups (heavy and very heavy drinkers) is allowed. It is overly clear that the very heavy drinkers placebo group had a strong placebo effect and started to drink less. So there is no reasons that groups could not be split.
- AUD has currently no strongly approved treatment (unmet need)
- The market is huge, which makes me think that a BP could make an offer on this (low amount of outstanding shares, low price, this is pocket money and for ADIL it would be bingo. win-win)
- ADIL PPS is mainly down because the play-press like the fool titled the trial as a failure and did not emphasize the value of the only group of interest: heavy drinkers (but what else is new). Created a perfect window of opportunity to get in low (below 2$).
- Management brings these results to US/European regulators and this looks like the best thing around for treatment of AUD. In all cases, and no matter the 0.007 stat. sig. if very heavy and heavy drinkers are joined, this still is better than whatever is out there now.
Note there is no real SOC (Standard of Care) for this, the best those AUD patients can get is some drug that has been approved for something else ( a neural condition) that probably (speculation) does them more harm then good.
I wanted to have this stock now (bought it at 1.49$ posting (HERE) that I expected it to go down even more because I placed a large AON order, and AON orders tend to have that effect).
The reason that I want it now, knowing that any regulators procedure will take at least 24 months is that I suspect that some BP will see the huge market and may be willing to place money in this because with the results at hand, doing a new heavy drinkers only clinical trial is nothing for BP. They up the participants and do the test way faster then anybody else, certainly with the current results to convince dockers in treatment centers.
So I want to be onboard now, because a thing like that happens WITHOUT any warning.
And for those of you that are in at even higher prices, 'don't panic' :)
AIMO
PS: I post mostly on the CDMO board here on IHUB because I follow things in depth and do not trade anymore (occasionally I do a trade, but mostly invest). I look at ADIL as an investment.
- Heavy drinkers are the biggest group and in practice are those that get help and treatment more than the very heavy drinkers. Very heavy drinkers have a stronger physiologic addiction and are more in denial.
- Stat. Sig. in heavy drinkers (0.003) is super for a near 90% response. Splitting groups (heavy and very heavy drinkers) is allowed. It is overly clear that the very heavy drinkers placebo group had a strong placebo effect and started to drink less. So there is no reasons that groups could not be split.
- AUD has currently no strongly approved treatment (unmet need)
- The market is huge, which makes me think that a BP could make an offer on this (low amount of outstanding shares, low price, this is pocket money and for ADIL it would be bingo. win-win)
- ADIL PPS is mainly down because the play-press like the fool titled the trial as a failure and did not emphasize the value of the only group of interest: heavy drinkers (but what else is new). Created a perfect window of opportunity to get in low (below 2$).
- Management brings these results to US/European regulators and this looks like the best thing around for treatment of AUD. In all cases, and no matter the 0.007 stat. sig. if very heavy and heavy drinkers are joined, this still is better than whatever is out there now.
Note there is no real SOC (Standard of Care) for this, the best those AUD patients can get is some drug that has been approved for something else ( a neural condition) that probably (speculation) does them more harm then good.
I wanted to have this stock now (bought it at 1.49$ posting (HERE) that I expected it to go down even more because I placed a large AON order, and AON orders tend to have that effect).
The reason that I want it now, knowing that any regulators procedure will take at least 24 months is that I suspect that some BP will see the huge market and may be willing to place money in this because with the results at hand, doing a new heavy drinkers only clinical trial is nothing for BP. They up the participants and do the test way faster then anybody else, certainly with the current results to convince dockers in treatment centers.
So I want to be onboard now, because a thing like that happens WITHOUT any warning.
And for those of you that are in at even higher prices, 'don't panic' :)
AIMO
PS: I post mostly on the CDMO board here on IHUB because I follow things in depth and do not trade anymore (occasionally I do a trade, but mostly invest). I look at ADIL as an investment.
All In My Opinion. I am not advising anything, nor accusing anyone.
Recent ADIL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 12:40:53 PM
- Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 08:21:54 PM
- Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 • GlobeNewswire Inc. • 04/29/2026 01:07:00 PM
- Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program • GlobeNewswire Inc. • 04/27/2026 12:47:00 PM
- Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial • GlobeNewswire Inc. • 04/22/2026 01:35:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 09:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/09/2026 09:00:04 PM
- Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans • GlobeNewswire Inc. • 03/24/2026 01:07:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 01:15:35 PM
- Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/06/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2026 10:03:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 01:17:24 PM
- Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement • GlobeNewswire Inc. • 03/03/2026 01:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 02:06:05 PM
- Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement • GlobeNewswire Inc. • 02/24/2026 02:00:00 PM
- Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One • GlobeNewswire Inc. • 02/23/2026 01:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 04:06:49 PM
- Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/17/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 09:30:34 PM
- Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 • GlobeNewswire Inc. • 02/04/2026 02:35:00 PM
